Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

IJIR publishes special/guest-edited issues and topical collections. The peer review process for articles included in topical collections/special issues is the same as the peer review process of the journal in general. Additionally, if the Guest Editors author an article in their topical collection/special issue, they will not handle the peer review process.​

Treatment of premature ejaculation with paroxetine hydrochloride


Aims of this study: To evaluate the efficacy of chronic and ‘on demand’ administration of paroxetine hydrochloride in the drug treatment of premature ejaculation (PE).

Materials and methods: Ninety-four normally potent men, aged 18–61 y (mean 39 y) with premature ejaculation were treated between January 1996 and March 1997, with oral paroxetine hydrochloride, a selective serotonin re-uptake inhibitor (SSRI). All men were either married or in a stable relationship. Sixty-four out of ninety-four men (Group A) were initially treated with paroxetine hydrochloride 20 mg administered once daily. Those men who responded with improved ejaculatory control within four weeks, were then treated with ‘on-demand’ paroxetine hydrochloride (20 mg) administered 3–4 h prior to planned intercourse. The remaining 33 out of 94 men (Group B) were initially treated with ‘on-demand’ paroxetine hydrochloride 20 mg administered 3–4 h prior to planned intercourse.

Results: The mean pre-treatment ejaculatory latency time (ELT) of both group A and B was 0.4 min (range 0–1 min) in 205 intercourses at a frequency of 0.4 intercourses PEr week. In group A after four weeks of daily administration of paroxetine, the mean ELT was 4.5 min (range 1-anejac.) in 761 intercourses at a frequency of 2.4 intercourses per week. Fifty-three out of sixty-one men in group A regarded their ejaculatory control as improved and were then treated with ‘on-demand’ paroxetine, achieving an ELT of 3.9 min (range 0–10) in 608 intercourses at a frequency of 2.6 intercourses per week. Thirty-six men in this group of 53 regarded that they had maintained improved ejaculatory control with a mean ELT of 5.5 min (range 2–20 min) after a further four weeks of treatment (P<0.001). The remaining 17 men reported a recurrence of poor ejaculatory control with a mean ELT of 0.7 min (range 0–2 min). In group B with initial ‘on-demand’ paroxetine after a mean of 4.5 weeks of treatment, the mean ELT was 1.5 min (range 0–5 min) in 298 intercourses at a frequency of 2.2 intercourses per week. Adverse effects were only recorded in men taking daily paroxetine and included anejaculation in 5 out of 61, inhibited orgasm in 3 out of 61 and reduced libido on 3 out of 61. Erectile dysfunction was not reported and ‘on demand’ paroxetine was not associated with any adverse effects.

Conclusions: Paroxetine hydrochloride appears to be a useful agent in the pharmacological treatment of premature ejaculation when administered on a chronic, an ‘on-demand’ basis following chronic treatment or initial ‘on demand’ basis.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type



Prices may be subject to local taxes which are calculated during checkout

Author information

Authors and Affiliations


Rights and permissions

Reprints and Permissions

About this article

Cite this article

McMahon, C., Touma, K. Treatment of premature ejaculation with paroxetine hydrochloride. Int J Impot Res 11, 241–246 (1999).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI:


  • premature ejaculation
  • paroxetine
  • anti-depressant drugs

This article is cited by


Quick links